相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization
Jeannine S. McCune et al.
CLINICAL CANCER RESEARCH (2014)
Pharmacokinetic-Directed Dose Adjustment Is Essential for Intravenous Busulfan Exposure Optimization: Findings From a Multi-Center Phase II Study of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma in North America
Michael Lill et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation
James A. Russell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide
Robert M. Dean et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen
Michelle Geddes et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Therapeutic drug monitoring of busulfan in transplantation
J. A. Russell et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study
L Nguyen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan plus cyclophosphamide for allogeneic bone marrow transplantation
JH Lee et al.
ANNALS OF HEMATOLOGY (2005)
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
M de Lima et al.
BLOOD (2004)
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality
A Kashyap et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Acute safety and pharmacokinetics of intravenous busulfan when used with oval busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2000)
分享论文
